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Abstract
Neuropathic pain can be a debilitating condition. Many types of drugs that have been used to treat neuropathic pain have
only limited efficacy. Recent studies indicate that pro-inflammatory mediators including tumor necrosis factor a (TNF-a) are
involved in the pathogenesis of neuropathic pain. In the present study, we engineered a gene therapy strategy to relieve
neuropathic pain by silencing TNF-a expression in the dorsal root ganglion (DRG) using lentiviral vectors expressing TNF
short hairpin RNA1-4 (LV-TNF-shRNA1-4) in mice. First, based on its efficacy in silencing TNF-a in vitro, we selected shRNA3
to construct LV-TNF-shRNA3 for in vivo study. We used L5 spinal nerve transection (SNT) mice as a neuropathic pain model.
These animals were found to display up-regulated mRNA expression of activating transcription factor 3 (ATF3) and
neuropeptide Y (NPY), injury markers, and interleukin (IL)-6, an inflammatory cytokine in the ipsilateral L5 DRG. Injection of
LV-TNF-shRNA3 onto the proximal transected site suppressed significantly the mRNA levels of ATF3, NPY and IL-6, reduced
mechanical allodynia and neuronal cell death of DRG neurons. These results suggest that lentiviral-mediated silencing of
TNF-a in DRG relieves neuropathic pain and reduces neuronal cell death, and may constitute a novel therapeutic option for
neuropathic pain.
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Introduction
Neuropathic pain is defined as pain caused by a lesion or disease
in the somatosensory nervous system [1]. Its severity varies but is
often so debilitating that it has been called ‘‘the most terrible of all
tortures, which a nerve wound may inflict’’ [2]. Neuropathic pain
is characterized by sensory abnormalities that range from
unpleasant abnormal sensations (dysesthesia), to an increased
response to painful stimuli (hyperalgesia), and to pain in response
to a stimulus that does not normally provoke pain (allodynia) [3].
These three kinds of pain are the most difficult types of chronic
pain to treat, and are often associated with autoimmune diseases
such as rheumatoid arthritis or Sjo¨gren’s syndrome, metabolic
diseases such as diabetes mellitus, side effects of drugs for cancer or
HIV chemotherapy, toxin exposure, infection and trauma [4–7].
Neuropathic pain impairs a patient’s daily activities and quality of
life. Currently available treatments for neuropathic pain include
sodium channel blockers, anti-depressants and anti-epileptic drugs,
but they are grossly inadequate; novel treatment methods with
better efficacy are much needed.
A number of animal models have been developed that can be
used to study the mechanism of neuropathic pain and to examine
the efficacy of new therapies [8]. For example, L5 spinal nerve
injury mouse models are widely used, so is the modified spinal
nerve ligation model [9], in which severe mechanical allodynia
and hyperesthesia occur without motor deficit. Another model, the
spinal nerve transection (SNT) mice [10] requires skillful surgery;
these mice display a stable type of neuropathic pain and is
especially suitable for pain studies and behavioral tests.
Recently, peripheral nerve and spinal nerve injury models have
also been used for research into the pathogenesis of neuropathic
pain. Studies in these models revealed that pro-inflammatory
mediators, such as tumor necrosis factor a (TNF-a), interleukin
(IL)-1b and IL-6, are up-regulated in the dorsal root ganglion
(DRG) and may be important mediators of neuropathic pain in
rodents [7,11–15]. Of note, TNF-a signaling was shown to
stimulate sensory neuronal excitability [16] and produce neuro-
pathic pain [17,18]. TNF-a and caspase-related signaling path-
ways also result in cell death and neuropathic pain [19],
establishing TNF-a expression in the DRG as a key mediator of
neuropathic pain. In addition, we previously reported that TNF-a
was involved in the pathogenesis of diabetic neuropathy in mice
and that inactivation or inhibition of TNF-a ameliorated diabetic
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neuropathy and reduced hyperalgesia [20,21]. In nondiabetic
injury neuropathic pain models, the inhibition of TNF-a also
reduced neuropathic pain-related behavior [13,22–24]. Further-
more, in human studies, TNF-a was found to be up-regulated in
sensory nerve and DRG, and contributed to neuropathic pain in
sensory neuronopathy, inflammatory diseases or nerve injury
[7,25–27]. We therefore hypothesized that TNF-a may be a
suitable therapeutic target for the treatment of neuropathic pain
and neuropathy. Indeed, human studies have suggested that anti-
TNF-a drugs ameliorate neuropathic pain and neuropathy in
Sjo¨gren’s syndrome [25], sciatica and disc-herniation [28–30].
However, the need for these drugs to be delivered systemically led
to serious side effects such as infection, interstitial pneumonia and
liver failure because generalized TNF-a inhibition suppresses the
normal immune system. Thus, to avoid inducing systemic side
effects, we selected the local administration of gene delivery
vectors to target the TNF-a at the site of injection.
Here, we present a gene therapy strategy that relieves SNT-
induced neuropathic pain by silencing TNF-a expression in DRG
using RNA interference technology with lentiviral vectors. This
strategy was effective in suppressing neuropathic pain and
protecting DRG neurons from cell death. These results constitute
a proof of principle that the therapeutic strategy can potentially be
used to treat neuropathic pain and sensory neuronopathy in
people.
Materials and Methods
Ethics statement
All animal protocols were approved by the Institutional Animal
Care and Use Committee of Shiga University of Medical Science
(Approved Number: 2012-8-5). All procedures were performed in
accordance with the guidelines of the Research Center for Animal
Life Science of Shiga University of Medical Science.
Construction of mouse TNF-a over-expression or
silencing plasmids for lentiviral vectors
The full-length mouse TNF-a cDNA was inserted into pLL3.7
plasmid including elongation factor 1 (EF-1) promoter and DsRed
as a reporter gene (TNF-a over-expression plasmid: LV-TNF-
DsRed). Four short hairpin RNAs (shRNA) were individually
inserted into pLL3.7 plasmid including U6 promoter and
enhanced green fluorescent protein (GFP), as a reporter gene,
driven by cytomegalovirus (CMV) promoter (TNF-a silencing
plasmid: LV-TNF-shRNA1-4). The full-length TNF-a coding
sequence (NM_013693) was isolated from RAW cells with
lipopolysaccharide stimulation. shRNA sequences against mouse
TNF-a were designed using a web site from The RNAi
Consortium (TRC) algorithm (Available: http://www.
broadinstitute.org/rnai/trc. Accessed on 2014 Feb 20.).
Production of mouse TNF-a over-expressing or silencing
lentiviral vectors
To produce recombinant lentiviral particles, psPAX2 (a
packaging plasmid), pMD2.G (an envelope plasmid, which has
the vesiculo-stomatitis virus G-protein), a gift of Dr. Didier Trono
(E´cole Polytechnique Fe´de´rale de Lausanne, Switzerland), and
TNF-a over-expression plasmid (or silencing plasmid) were co-
transfected into 293T cells using the calcium phosphate method as
described previously [31]. After 6 h incubation, the culture
medium was exchanged. Culture medium containing lentiviral
particles was collected after 48 h incubation, and was filtered
through a 0.45 mm pore size cellulose acetate filter. Lentiviral
vectors were concentrated using Lenti-X Concentrator (Takara
Bio Inc., Otsu, Japan), and were stocked at a concentration of
1.86108 infectious units (IFU)/ml at 280uC after the determina-
tion of IFU using 293T cells. Finally, we produced LV-TNF-
DsRed (mouse TNF-a and DsRed expression vector), LV-GFP
(control vector expressing GFP without shRNA sequence) and LV-
TNF-shRNA1-4 (TNF-a silencing vector with GFP expression).
Co-infection test of mouse TNF-a over-expressing and
silencing lentiviral vectors
One day before infection, 293T cells were split to 6 well-culture
dishes at a density of 1.06105 cells per well. The confluency of
293T cells was approximately 70% at the time of infection. At 6 h
after infection of LV-TNF-DsRed (3.66105 IFU), 3.66105 IFU
LV-GFP or LV-TNF-shRNA1-4 was separately added into each
well of LV-TNF-DsRed-infected 293T cells. At 72 h later, DsRed
and GFP expression were observed under fluorescence microscopy
and TNF-a mRNA expression was determined by quantitative
RT-PCR analysis.
Animals
Male 9–10 week-old C57BL6 (Japan CLEA, Osaka, Japan)
mice weighing 19.0–22.0 g were used in this study. The mice were
housed in separated cages and the room kept under 12:12 light-
dark cycle with free access to food and water.
Surgical procedures
The neuropathic pain model by L5 spinal nerve transection
(SNT) was generated by the method described previously
(Figure 1A) [9,10]. Briefly, mice were anesthetized by intraper-
itoneal administration of sodium pentobarbital (5 mg/kg). After
the midline incision of mouse back skin, the bilateral L5 transverse
processes of the lumbar spine were clearly removed. Bilateral L5
spinal nerves were exposed on the visual field. Only the left nerve
was pinched and transected. Immediately after transection, 1 ml
(1.86105 IFU/ml) of lentiviral vector was injected onto proximal
transected site of left L5 spinal nerve using a Hamilton syringe
(8001 1701LT, Hamilton company, Nevada, USA) with a 30G
needle. The right spinal nerve, as a control side, was clearly
exposed without transection or administration of lentiviral vector.
Behavioral test
Mechanical allodynia was assessed prior to injury (day -2) and at
1, 3, 5, 7, 10 and 14 days after SNT, using a dynamic planter
aesthesiometer (Ugo Basil, Varese, Italy) as described previously
[32]. Paw withdrawal in response to mechanical stimuli was
measured. Briefly, each mouse was placed in a polypropylene box
with a metallic mesh floor and allowed to acclimatize to the testing
environment for at least 1 h. A stimulating filament probe was
positioned under the hind paw, which was gradually applied until
mice withdrew their paw. The pressure was increased at
approximately 10 g/mm2/sec. The test was performed on both
the intact right or neuropathic left hind paw. The withdrawal
threshold was determined by mean of three trials.
Reverse transcription-PCR and quantitative RT-PCR
analysis
Animal tissues were removed under deep anesthesia and
immediately frozen in liquid nitrogen. Total RNA was extracted
from cultured cells and frozen tissues using RNeasy mini kit
(Qiagen, Valencia, CA) with DNase I (Rnase-free DNase set,
Qiagen) treatment. Reverse transcription was performed from
100 ng of total RNA in each tube using Prime Script perfect Real
time (Takara Bio Inc.).
Gene Therapy for Neuropathic Pain by TNF-a shRNA
PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e92073
RT-PCR was performed with the following primers: 59-
CACGTCGTAGCAAACCACCAAGTGG-39 and 59-GATAG-
CAAATCGGCTGACGGTGTGG-39 for mouse TNF-a, 59-
AGGACGACGGCAACTACAAGAC-39 and 59-GAAGTT-
CACCTTGATGCCGTTC-39 for GFP, 59-AAATCCCATCAC-
CATCTTCCA-39 and 59-AATGAGCCCCAGCCTTCTC-39
for human GAPDH (for 293T cell), 59-AACGACCCCTTCATT-
GAC-39 and 59-TCCACGACATACTCAGCAC-39 for mouse
GAPDH (for mouse tissues). For RT-PCR by TaqMan method,
the following primers were used: Mn_99999915_g1 (Invitrogen,
Carlsbad, USA) for mouse GAPDH and 59-CATCTTCT-
CAAAATTCGAGTGACAA-39, 59-TCGGAGTAGACAAGG-
TAGAACCC-39 and 59-FAM-GCACGTCGTAGCAAACCAC-
CACCAAGTGGA-TAMRA-39 (probe) for mouse TNF-a. The
PCR reaction consisted of denaturation at 94uC for 30 seconds,
annealing at 60uC for 30 seconds, extension at 72uC for 30
seconds. The PCR products were analyzed with FAS-IV (Japan
Genetics, Tokyo, Japan).
For quantification of each gene, real time PCR assay was
performed using a LightCycler 480 (Roche Diagnostics, Manheim,
Germany) with SYBR Green method (for activating transcription
factor 3 (ATF3), calcitonin gene related peptide (CGRP), IL-6,
Figure 1. L5 spinal nerve transection as a neuropathic pain model. (A) Schematic presentation of left L5 spinal nerve transection (SNT)
surgical procedure. Left and middle panels show the anatomical enlargement scene of the same field as the square of the mouse back in the right
panel. The left panel shows a schematic view of the middle panel picture. The double lines show the L5 spinal nerve transection site in the left and
middle panels. (B) The threshold of mechanical allodynia in the neuropathic model mice induced by SNT for 14 days. Black circles indicate ipsilateral
and white circles indicate contralateral responses for mechanical stimuli. The threshold values were measured for five mice at each time point. Data
show means 6 S.E. *p,0.01. (C) TNF-a mRNA expression in bilateral L5 DRG of neuropathic pain model mice for 14 days after SNT. The data are
normalized to GAPDH and presented as the relative ratio to naı¨ve DRG (no SNT mice) (n = 3–5 per each time course group). Gray bar is naı¨ve DRG
group, black bars are ipsilateral L5 DRG group, and open bars are contralateral L5 DRG group. Bars show means 6 S.E. **p,0.05, compared with
naı¨ve.
doi:10.1371/journal.pone.0092073.g001
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neuropeptide Y (NPY), human GAPDH, mouse GAPDH and
mouse TNF-a) and TaqMan method (for mouse GAPDH and
mouse TNF-a). The PCR parameters were one cycle of 95uC for
three min, followed by 50 cycles of denaturation at 95uC for
30 sec, annealing at 60uC for 30 sec and extension at 72uC for
30 sec. The emitted fluorescence for each reaction was measured
three times during the annealing extension phase, and amplifica-
tion plots were analyzed using LightCycler 480 software, version
1.5 (Roche Diagnostics Manheim, Germany). Potential genomic
DNA contamination was controlled by the use of intron-
encompassing primers and DNase digestion. GAPDH and
MAPK6 have been reported to be the most stable reference
genes for use in normalizing transcript level of interest genes
although the expression of other many house-keeping genes
reduced on the early phase in DRG after nerve injury [33].
Therefore, the normalization and relative expression analysis of
target genes were performed using the 22DDCt method with
GAPDH as a control, which expression levels were confirmed not
to be changed among day -2, 3, 7 and 14.
Immunohistochemistry
Animals were anesthetized by intraperitoneal administration of
sodium pentobarbital (50 mg/kg) and intracardially perfused with
30 ml of PBS followed by a fixative containing 4% paraformal-
dehyde in 0.1 M PB. After perfusion fixation, animal tissues were
kept in the same fixative at 4uC for 18 h and permeated with 15%
(w/v) sucrose buffer with agitation. Each tissue was embedded in
Tissue-Tek O.C.T compound (Sakura, Tokyo, Japan), frozen with
liquid nitrogen and cut on a cryostat at 8 mm sections collected on
MAS (Matsunami aggressive silane)-coated glass slides. Sections
were blocked with 3% normal goat serum in PBS at room
temperature for 15 min and processed for immunohistochemistry.
The following antibodies were used: anti-TNF-a (1:100, Abcam,
Cambridge, United Kingdom), anti-GFP (1:100, Medical &
Biological Laboratories, Nagoya, Japan), anti-cleaved caspase3
(1:100, Cell Signaling Technology Japan, Tokyo, Japan), and
AlexaFluor 488, 594 and 633 (1:1000, Abcam) as primary and
secondary antibodies. For marker stains, we used 49,6-diamidino-
2-phenylindole (DAPI) for nuclei and fluorescent Nissl (Neuro-
Trace 435/455 or 530/615, Molecular Probes, Eugene, Oregon,
USA) for neurons. Fluorescence images were captured and
analyzed using Nikon C1si and the software, EZ-C1 version
3.90 (Nikon, Tokyo Japan).
DRG neuron cell count
To evaluate the neuronal cell survival in ipsilateral L5 DRG
after SNT, we perfused mice transcardially with 4% paraformal-
dehyde in 0.1 M PBS, and isolated DRG tissues and embedded
them in paraffin. L5 DRG paraffin blocks were sectioned at 10 mm
thickness and stained with 0.1% Cresyl violet (Nissl stain, Muto
Pure Chemicals Co. Ltd, Tokyo, Japan). After Nissl staining
(Cresyl violet), all visible neurons in each left L5 DRG were
counted in consecutive sections (20 mm intervals). For the
evaluation of apoptosis after SNT with or without gene therapy,
we counted the number of cleaved caspase3 positive neurons.
Approximately 300 neurons were analyzed in consecutive sections
(30 mm intervals) for each left L5 DRG.
Transduction efficacy and treatment effects of gene therapy by
lentiviral vector in vivo were evaluated by counting the number of
GFP or TNF-a positive neurons with the neuronal marker stain of
fluorescent Nissl (NeuroTrace 435/455 for GFP or NeuroTrace
530/615 for TNF-a) in DRG after SNT with or without gene
therapy. We analyzed approximately 300 neurons in consecutive
sections (30 mm intervals) for each L5 DRG.
Statistical analysis
Statistical analysis was performed with SPSS 17.0 software
(SPSS Inc., Chicago, USA). All data are shown as mean 6
standard error of the mean (S.E.). The one-way ANOVA followed
by Tukey’s test was used to calculate statistical significance for
multiple data sets. For behavioral test, two-way ANOVA was used.
Data were considered significant difference at p,0.05.
Results
TNF-a expression and behavior testing in a spinal nerve
transection (SNT) mouse model of neuropathic pain
We induced neuropathic pain in mice by SNT on the left side of
the L5 spinal nerve at a location close to the spine (ipsilateral side,
Figure 1A). The right L5 spinal nerve was not transected
(contralateral side). SNT induced severe mechanical allodynia and
hyperesthesia in the ipsilateral hind paw. We measured the hind
paw withdrawal threshold against the mechanical stimuli (me-
chanical threshold) for the ipsilateral and contralateral paws for 14
days after SNT and found that the threshold was markedly
decreased the day after SNT and remained at the same low level
for 14 days (Figure 1B). We quantified TNF-a mRNA expression
in L5 DRG by RT-PCR on day 1, 3, 7 and 14 after left SNT-
induced neuropathic pain (Figure 1C) and found that SNT led to
elevation of TNF-a mRNA expression in the DRG on the
ipsilateral side, which was approximately 2.5-fold higher than the
level in the naı¨ve L5 DRG on day 3 and 7 after SNT, and
returned towards baseline levels on day 14 after SNT (Figure 1C).
Design and evaluation of shRNA sequences against TNF-
a expression in cultured cells
To develop an shRNA gene therapy against TNF-a in the SNT
model, we designed 4 candidate shRNA sequences against TNF-a
based on scoring algorithms presented by The RNAi Consortium
(TRC, available: http://www.broadinstitute.org/rnai/trc. Ac-
cessed on 2014 Feb 20.) (Target sites of these four shRNA against
mouse TNF-a are shown in Figure 2A). We cloned the individual
shRNA sequences (shRNA1-4 in Figure 2A) into a pLL3.7
plasmid to produce lentiviral vectors designated LV-TNF-
shRNA1-4 (Figure 2B). In these vectors, the shRNA sequence
was driven by the U6 promoter and the GFP was driven by the
CMV promoter (Figure 2B).
We created TNF-a-expressing 293T cells by infecting them with
lentiviral vector over-expressing TNF-a and DsRed driven by EF-
1 promoter (LV-TNF-DsRed in Figure 2B). We next tested the
capacity of LV-TNF-shRNA1-4 to silence TNF-a expression by
infecting these cells with LV-TNF-shRNA1-4 or LV-GFP (control
GFP vector with no shRNA sequence). Seventy-two hours later,
we observed these cells under the fluorescence microscope. We
found that in the LV-TNF-shRNA1-4 and LV-GFP groups, the
GFP signals were similar in 293T cells (lower panels in Figure 2C)
confirming approximately similar level of infection of the 4
silencing vectors. In cells that were infected with silencing vectors
(LV-TNF-shRNA1-4), the DsRed signal was markedly attenuated
in all 4 groups compared with the LV-GFP group or single
infection LV-TNF-DsRed (‘none’ group) (upper panels in
Figure 2C). Next, we quantified TNF-a mRNA expression by
RT-PCR and found that the level of TNF-a mRNA was
significantly reduced in the 4 LV-TNF-shRNA groups compared
with LV-GFP control group (n = 5, p,0.01, the relative percent
lowering in mRNA level were as follows: 47.8% by LV-TNF-
shRNA1, 75.1% by LV-TNF-shRNA2, 89.1% by LV-TNF-
shRNA3, and 84.7% by LV-TNF-shRNA4; Figure 2D). Thus,
of the 4 vectors that we analyzed, we found LV-TNF-shRNA3 to
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Figure 2. Construction of mouse TNF-a over-expression and shRNA lentiviral vectors and silencing efficacy of LV-TNF-shRNAs. (A)
Four candidate shRNA sequences against TNF-a (shRNA1 to shRNA4) and schematic presentation of target site of these shRNAs on mouse TNF-a
sequence. The black bars and the number 1 to 4 under the scheme of mouse TNF-a cDNA indicate the location of mouse TNF-a cDNA targeted by
shRNA1-4. The numbers in the parentheses beside shRNA1-4 mean the location of target site against the mouse TNF-a cDNA. (B) Schematic
presentation of LV-TNF-DsRed (TNF-a over-expression vector, upper) and LV-TNF-shRNA1-4 (TNF-a silencing vector, lower). LTR: long terminal repeat,
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be the most efficacious in silencing TNF-a expression in 293T
cells. We therefore tested the efficacy of using LV-TNF-shRNA3
therapy on neuropathic pain in the SNT mouse model.
Evaluation of transduction efficiency with LV-TNF-
shRNA3 injection onto left L5 spinal nerve
We determined the efficiency of gene delivery after the
treatment by histological analysis and mRNA expression of GFP
(reporter gene) in bilateral DRG tissues after infection of LV-TNF-
shRNA3 targeting the transected left L5 spinal nerve. Infection-
induced GFP mRNA expression in ipsilateral L5 DRG was
confirmed between day 3 to day 14 after local injection onto the
left L5 spinal nerve (Figure 3A). mRNA expression was also
observed in the contralateral L5 DRG, but the expression levels
were much lower compared with the ipsilateral side. GFP mRNA
expression in ipsilateral L5 DRG gradually increased from day 3
to day 14, which was also observed in the contralateral side
although the expression was significantly lower (complete set of
data from all treated mice, corrected to GAPDH expression,
Figure 3A). In addition, GFP protein signals were detected
mainly in neurons of L5 ipsilateral DRG sections, which
population gradually increased and reached 43.2%66.1% on
day 14 (Figure 3B, C). In L5 contralateral DRG, GFP protein
signals were observed at 1 level significantly lower than in the
ipsilateral DRG, reaching 18.9%63.0% of the neurons on day 14
(Figure 3B, C). Therefore, administration of LV-TNF-shRNA3
induced high level of transgene expression in DRG tissues by local
injection onto the spinal nerve.
LV-TNF-RNA3 suppressed TNF-a expression in ipsilateral
L5 DRG after SNT
We quantified the relative degree of TNF-a silencing after LV-
TNF-shRNA3 gene therapy by quantitative RT-PCR of TNF-a
mRNA and immunohistochemistry of TNF-a protein in L5 DRG
tissues. In SNT with LV-GFP group (control group), TNF-a
mRNA expression increased approximately 4-fold compared with
pretreatment expression levels in ipsilateral L5 DRG from day 3 to
day 14 (left panel in Figure 4A). The increased TNF-a mRNA
expression by SNT was markedly suppressed down to baseline
levels in ipsilateral L5 DRG treated with LV-TNF-shRNA3
(therapy group) for 14 days (left panel in Figure 4A). In the
contralateral L5 DRG, there was no significant change in TNF-a
mRNA levels in the untreated LV-GFP groups (control group).
The LV-TNF-shRNA3 group also did not show any change (right
panel in Figure 4A). Immunohistochemistry in ipsilateral L5
DRG revealed markedly increased immunoreactive TNF-a in the
cytosol of neurons after ipsilateral SNT in the LV-GFP group
compared with naı¨ve (control group) from day 3 to day 14
(Figure 4B, C). The immunostained TNF-a positive neurons (co-
localized with Nissl stain) increased markedly in SNT with LV-
GFP group compared with pretreatment DRG group (naı¨ve) from
day 3 to day 14 (the percentage of positive neuron were increased
approximately 60% and peaked at day 7, Figure 4B). In gene
therapy group with LV-TNF-shRNA3, the appearance of
immunoreactive TNF-a-positive neurons induced in the vast
majority of the DRG neurons by SNT was suppressed to baseline
levels from day 3 to day 14 (Figure 4B, C). These results were
consistent with the data on the level of TNF-a mRNA expression.
LV-TNF-RNA3 preserves DRG neurons from cell death
caused by SNT
SNT induced cell death leading to reduced neuron number was
reported to correlate with neuropathic pain [34]. We therefore
used Nissl staining to quantify the number of surviving DRG
neurons in ipsilateral L5 DRG in LV-GFP and LV-TNF-shRNA3
treatment groups on day 14 after SNT (Figure 5A, B). Neuronal
cell numbers were significantly reduced by SNT in the ipsilateral
L5 DRG in LV-GFP group (709.86119.1 cells/DRG tissue)
compared to naı¨ve (22646260.3 cells/DRG tissue) (Figure 5A,
B). In contrast, DRG neuronal cell numbers were significantly
preserved in the LV-TNF-shRNA3 treatment group (15016154.8
cells/DRG tissue) compared with the LV-GFP group (Figure 5A,
B).
We next used immunohistochemistry of cleaved caspase3 to
quantify the number of apoptotic neurons in L5 ipsilateral DRG
on day 14 after SNT and the therapeutic effects of TNF-a
silencing. We detected a very low level of cleaved caspase3-
immunoreactive DRG neurons under naı¨ve basal conditions
(3.3561.00%, Figure 6A, B). However, the number of cleaved
caspase3-positive neurons in ipsilateral L5 DRG 14 days after
SNT increased significantly in the LV-GFP group (16.5261.56%);
this SNT-induced increase in number of apoptotic cells was
significantly suppressed by LV-TNF-shRNA3 treatment (to
9.0961.14%) (Figure 6A, B).
LV-TNF-shRNA3 reduces mRNA expression of
neuropeptides, injury and inflammatory markers related
to neuropathic pain
Many injury markers, cytokines and neuropeptides have been
reported to be up-regulated in DRG neurons in mouse models of
neuropathic pain. Thus, we measured the mRNA expression of
the injury makers ATF3 and NPY, the inflammatory cytokine IL-
6, and the neuropeptide CGRP in ipsilateral L5 DRG to evaluate
the effect of TNF-a silencing. Both ATF3 and NPY mRNA levels
increased markedly after SNT. The ATF3 mRNA peaked early at
day 3, whereas NPY mRNA increased significantly at day 3 but
peaked later at day 7 after SNT (Figure 7A, B). The peak ATF3
expression was significantly suppressed on day 3 and that of NPY
was significantly suppressed on days 3 and 7 in the LV-TNF-
RNA3 group compared with the LV-GFP group (Figure 7A, B).
IL-6 mRNA expression was significantly elevated in L5 DRG by
SNT in the LV-GFP group on day 3 (Figure 7C), and the level
was significantly attenuated in the LV-TNF-shRNA3 group on
day 3 (Figure 7C). We detected no significant change in the
mRNA expression of CGRP, a neurotransmitter correlated with
pain transmission (Figure 7D), and its level was not changed by
LV-TNF-shRNA treatment (Figure 7D).
Y: packaging signal, EF-1: elongation factor 1 promoter, IRES: internal ribosome entry sites, SIN-LTR: self inactivating-LTR, CMV: cytomegalovirus
promoter. (C) Fluorescence in 293T cells at 72 h after co-infection with two lentiviral vectors, LV-TNF-DsRed and LV-TNF-shRNA1-4, LV-GFP (GFP
control vector with no TNF-shRNA sequence) or none. Upper panels show TNF-a expression (red), lower panels show each transduction of LV-TNF-
shRNA1-4 therapeutic vectors or LV-GFP (green). Scale bar = 50 mm. (D) TNF-a mRNA expression in 293T cells at 72 h after infection of LV-TNF-DsRed
with LV-TNF-shRNA1-4, LV-GFP, or none (n = 5 per group). The data were normalized by GAPDH. Bars indicate means 6 S.E. *p,0.01 compared with
LV-GFP group.
doi:10.1371/journal.pone.0092073.g002
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LV-TNF-shRNA3 gene therapy for neuropathic pain in the
SNT mouse model
While we analyzed the various biochemical and immunohisto-
chemical parameters induced by SNT, we also monitored the
efficacy of LV-TNF-shRNA3 or LV-GFP (control vector) treat-
ment by measuring the mechanical threshold every other day till
day 7 and again on day 10 and 14 after treatment (Figure 8). The
mechanical threshold in the ipsilateral hind paw was significantly
impaired in both groups from day 1 to day 14, but the impairment
was significantly attenuated throughout this period in the LV-
TNF-shRNA3 group compared with the LV-GFP (control vector)
group. Therefore, the LV-TNF-shRNA3 treatment led to an
improvement in an objective behavior measurement in neuro-
pathic pain in SNT mice.
Discussion
This study demonstrated that silencing of TNF-a expression
with lentiviral vectors suppressed neuropathic pain induced by
SNT. Lentiviral vectors targeted to DRG tissues decreased TNF-a
expression in the affected (ipsilateral) DRG neurons. In addition,
silencing of TNF-a expression in DRG resulted in the inhibition of
Figure 3. Transduction efficacy of LV-TNF-shRNA3 onto left L5 spinal nerve in L5 DRG tissues. (A) The quantification of GFP mRNA
expression induced by LV-shRNA3 in bilateral L5 DRG on day 3, 7, 14 after SNT and injection of LV-TNF-shRNA3. The data were normalized to GAPDH.
Black bars showed the results in ipsilateral L5 DRG (n = 5 per time point) and open bars showed the results in contralateral L5 DRG (n = 5 per time
point). Bars indicate means 6 S.E. *p,0.05. (B) The population of GFP positive neurons in L5 DRG on day 3, 7 and 14 after SNT and injection of LV-
TNF-shRNA3. Black bars showed the results in ipsilateral L5 DRG (n = 5 per time point) and open bars showed the results in contralateral L5 DRG (n = 5
per time point). Bars indicate means 6 S.E. *p,0.05, **p,0.01. (C) Immunohistochemical staining with anti-GFP antibodies (green), DAPI (blue) and
Nissl (red) in the bilateral L5 DRG on day 3, 7 and 14 after SNT and injection of LV-TNF-shRNA3. Upper panels of each group showed immunostainigs
of anti-GFP antibodies and 2nd lines’ panels showed the merged images of GFP, Nissl and DAPI in each group. The square regions of 2nd lines’ panels
were enlarged in third lines’ panels in ipsilateral L5 DRG group. Scale bar = 50 mm.
doi:10.1371/journal.pone.0092073.g003
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neuronal cell death and apoptosis caused by SNT. Furthermore,
injury markers and inflammatory cytokines that were up-regulated
by SNT were greatly attenuated by lentiviral gene therapy.
Therefore, gene therapy-mediated TNF-a silencing may be an
efficacious treatment strategy for protecting DRG neurons and
ameliorate neuropathic pain induced by nerve injury.
Neuropathic pain and TNF-a
Neuropathic pain is caused by neuronal damage or dysfunction
[1,35]. Recent studies suggest that a communication between the
immune and the nervous systems may underlie neuropathic pain
[11]. TNF-a is a pro-inflammatory cytokine commonly produced
in response to different types of disease, inflammation and tissue
damage. It is a short-lived inflammatory mediator that plays a
central role in initiating inflammatory reactions of the innate
immune system, including the induction of other cytokine
production, activation and expression of adhesion molecules,
Figure 4. Suppression of TNF-a mRNA and protein expression in L5 DRG of SNT mice by LV-TNF-shRNA3. (A) TNF-a mRNA expression
in bilateral L5 DRG from LV-GFP or LV-TNF-shRNA3 groups on day 3, 7, 14 after SNT and injection. Ipsilateral L5 DRG (left panel) and contralateral L5
DRG (right panel). The data are normalized to GAPDH and presented as a relative ratio to naı¨ve DRG (on day 22). Gray bars showed the result in naı¨ve
DRG (on day 22, n = 6), white bars showed the results in LV-GFP group (n = 6–8 per time point) and black bars showed the results in LV-TNF-shRNA3
group (n = 6–8 per time point) Bars indicate means 6 S.E. *p,0.05, #p,0.05 compared with naı¨ve, ##p,0.01 compared with naı¨ve, { the difference
was not significant compared with naı¨ve. N.S. means ‘‘not significant.’’ (B) The population of TNF-a positive neurons in ipsilateral L5 DRG on day 3, 7
and 14 after SNT and injection of LV-GFP or LV-TNF-shRNA3. Gray bars showed the result in naı¨ve DRG without SNT and injection (on day 22, n = 4),
white bars showed the results in LV-GFP group (n = 4–5 per time point) and black bars showed the results in LV-TNF-shRNA3 group (n = 4–5 per time
point) Bars indicate means 6 S.E. ** p,0.01, ##p,0.01 compared with naı¨ve, { the difference was not significant compared with naı¨ve. (C)
Immunohistochemical staining with anti-TNF-a antibodies (red) and Nissl (blue) in the ipsilateral L5 DRG on day 3, 7 and 14 after SNT and injection of
LV-GFP or LV-TNF-shRNA3. Upper panels of each group showed immunostainigs of anti-TNF-a antibodies and lower panels showed the merged
image of TNF-a and Nissl in each group. Scale bar = 50 mm
doi:10.1371/journal.pone.0092073.g004
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and stimulation of inflammatory cells in nerve injury [36]. Indeed,
the direct application of TNF-a to the sciatic nerve and DRG
leads to changes in the properties of neurons, such as ectopic firing
in Ad-, Ab- and C-fibers [37,38], and induces thermal hyperal-
gesia and mechanical allodynia [18,39,40]. Furthermore, TNF-a
enhances TTX-R Na+ channels and increases membrane K+ ion
conductance by a non-voltage-gated mechanism in DRG neurons
[41,42]. Therefore, TNF-a plays a pivotal role in multiple
pathways involved in neuropathic pain and is clearly a treatment
target for neuropathic pain. Here we found that silencing TNF-a
in DRG partially suppressed mechanical allodynia though it did
not produce a complete remission. Other cytokines, neurotrophic
factors and chemokines such as IL-1b, nitric oxide, ATP,
chemokine(C-C motif) ligand 2 and nerve growth factor, are
involved in the pathogenesis of neuropathic pain, and they have
direct actions as well as mediate crosstalks with TNF-a in
nociceptive cascade in DRG neurons [43]. It is likely that the
directed modulation of these molecules, in addition to TNF-a
suppression, may be required for a more robust clinical remission
of the neuropathic pain. Nonetheless, this study showed that gene
therapy-mediated TNF-a-silencing is a useful strategy for the
treatment of neuropathic pain.
Association between TNF-a and apoptosis or
inflammation in spinal nerve injury
Spinal nerve injury leads to activated caspase3 and increased
apoptosis [34] in DRG neurons [44,45]. TNF-a was known to be
associated with apoptosis through the activation of caspase3
pathway [46]. In this study, TNF-a expression and caspase3 were
elevated in DRG tissues 14 days after SNT, and we showed that
TNF-a silencing in this setting suppressed caspase3 and increased
the number of surviving DRG neurons. Therefore, silencing TNF-
a not only suppresses neuropathic pain but also protects DRG
neurons from apoptotic cell death after SNT, an effect that may
have an impact on the functional maintenance and regeneration
potential of sensory neurons.
IL-6 is up-regulated in DRG in response to peripheral nerve
injury [47,48]. A recent study suggested that TNF-a induces the
production of IL-6, which contributes to neuropathic pain in DRG
[49] and spinal cord in a spinal nerve transection model [47–49].
ATF3 and NPY are widely used as injury markers of axotomy.
These two molecules are also up-regulated in DRG neurons in
nerve injury models [50,51], and are associated with phenotypic
changes [52] in DRG neurons such as ion channel excitability and
responses against neuropeptides [53,54]. Here, we showed that
mRNA expression of ATF3, NPY and IL-6 is elevated in the early
Figure 5. Evaluation of survival neurons in L5 DRG after SNT with LV-TNF-shRNA3. (A) Nissl stain of L5 ipsilateral L5 DRG on day 14 after
SNT with LV-TNF-shRNA3 or LV-GFP. Scale bar = 50 mm. (B) Quantitative analysis of cell survival in L5 DRG neurons after SNT with LV-TNF-shRNA3 or
LV-GFP (n = 5 per group). Gray bar - neuronal cell numbers including single ipsilateral L5 DRG in naı¨ve DRG group; white bar - LV-GFP group; black bar
- LV-TNF-shRNA3 group. Bars show means 6 S.E. *p,0.01, #p,0.05 compared with naı¨ve, ##p,0.01 compared with naı¨ve.
doi:10.1371/journal.pone.0092073.g005
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phase after SNT but can be suppressed by TNF-a silencing,
indicating that TNF-a is likely up-stream of the immune cascade
during nerve injury. The multiple downstream effects of TNF-a
silencing protect DRG neurons against inflammation induced by
nerve injury by suppressing of ATF3, NPY and IL-6 expression,
resulting in the reduction of apoptosis and suppression of
neuropathic pain.
Benefits of lentiviral vector-mediated silencing of TNF-a
DRG-targeted gene delivery is a promising therapeutic option
for the treatment of neuropathic pain. A number of viral gene
vectors are available for gene delivery, including adenoviral (Ad)
vectors, adeno-associated viral (AAV) vectors, and lentiviral
vectors [55]. The selection of the appropriate viral vectors and
route of delivery are important issues that must be considered.
In general, Ad vectors have high transduction efficiency in most
cells with the coxsackie virus and adenovirus receptor (CAR)
compared to AAV and lentiviral vectors after attachment to the
target cells [56–58]. However, Ad vectors show relatively low
affinity for mature neuronal cells with rare CAR [56,59]. In using
AAV vectors for neural tissue transduction, several serotypes of
AAV vectors are known to show tropism to neurons [55,60]. In
lentiviral vectors, the tropism to the neurons is acquired by the
specific envelop protein [55,61–63]. In this study, we used
lentiviral vectors pseudotyped with vesiculo-stomatitis virus
glycoprotein for gene therapy of neuropathic pain because this
glycoprotein gives the letiviral vectors both the potential of tropism
for neuronal cells and an ability to infect neuronal cells by axonal
transport [63].
It is also important to consider the toxicity of various viral
vectors. Ad vectors have been shown to induce a potent immune
response against the capsid, double-stranded DNA genome, viral
proteins expressed from the vector backbone, or incorporated
transgenes, a limitation for in vivo gene therapy [64]. In contrast,
AAV and lentiviral vectors generally elicit a relativelymild immune
response as compared to Ad vectors [55,64]. Using lentiviral
vectors might lead to a relatively mild immune response, when
used in vivo in rodents [55,56,62].
For delivering transgenes by viral vectors to the DRG in vivo, it
was reported mainly by three different approaches, intrathecally,
direct injection into sciatic nerve or into the DRG itself [55,60–
62,65,66]. A prior study using AAV vectors suggested that the
direct injection of the vectors into the DRG or sciatic nerve could
provide stronger gene expression in the DRG neurons than
injection into subcutaneous tissue or subarachnoid space [65].
Moreover, direct injection of Ad vector and AAV vector into
Figure 6. Immunohistochemical analysis of cleaved caspase3 in DRG tissues. Immunohistochemical staining of cleaved caspase3 (red) (A)
and the quantitative analysis of cleaved caspase3 positive neurons (B) in ipsilateral L5 DRG after spinal nerve transection with LV-TNF-shRNA3 or LV-
GFP on day 14 (n = 5 in each group). Bars show means 6 S.E. *p,0.01, #p,0.05 compared with naı¨ve, ##p,0.01 compared with naı¨ve. Scale bar
= 50 mm.
doi:10.1371/journal.pone.0092073.g006
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DRG was also reported to be vastly superior to intraneural
injection into sciatic nerve [66]. Lentiviral vectors have been
delivered to either directly into DRG or indirectly via the sciatic
nerve, which also ended up in the DRG [61,62]. In general, direct
DRG injection appears to be the most effective and widely used
approach. We note, however, that direct injection to DRG may
induce additional tissue damage. Especially for the treatment of
neuropathic pain, it is important to avoid further damage of the
sensory nerve system, which by itself may induce neuropathic pain
[67]. Here, we selected injection onto injury site of spinal nerve as
a promising approach.
Unexpectedly, we found that spinal nerve injection led to high
level transduction of the DRG. It was much higher than that
reported in a previous study that utilized direct injection of
lentiviral vectors into DRG in rats [62]. The administration
method of injection onto injury site of spinal nerve seems to
produce results from three different delivery methods, combining
the effects of intrathecal injection, direct sciatic nerve or DRG
injection. In fact, we demonstrated that GFP expression and
silencing of TNF-a occurred in the ipsilateral as well as
contralateral DRGs. The lentiviral vector might have spread
through the cerebrospinal fluid to the contralateral DRG. This
phenomenon is consistent with the expression pattern as transgene
was found to be diffusely expressed at many spinal levels of DRG
after intrathecal injection. At the same time, lentiviral vectors may
be delivered to the DRG neurons by axonal transport because
lentiviral vectors were injected onto spinal nerve in a manner
similar to that following sciatic nerve injection as previously
reports [56]. In our results, transgene was expressed diffusely in
DRG neurons, which was different from the expression pattern
immediately adjacent to the injection site following direct injection
into DRG. Finally, it is possible that lentiviral vectors may access
the ipsilateral DRG by direct infiltration. Here, we showed that
lentiviral vectors injected onto the injury site of the spinal nerves
led to high efficiency transduction of DRGs, constituting a
promising approach for delivering transgenes to the DRG,
Figure 7. mRNA expression of neuropeptides, inflammatory and injury markers in SNT mice L5 DRG with treatment. ATF3 (A), NPY
(B), IL-6 (C) and CGRP (D) mRNA expression were measured on day 3, 7 and 14 after SNT. The data are normalized to GAPDH. Gray bars - naı¨ve DRG
(on day 22); white bars - LV-GFP group; black bars - LV-TNF-shRNA3 group (n = 6–8 per group). Bars show means 6 S.E. *p,0.05, **p,0.01, #p,0.05
compared with naı¨ve, ##p,0.01 compared with naı¨ve. N.S. means ‘‘not significant’’.
doi:10.1371/journal.pone.0092073.g007
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although further studies should be needed to clarify the details of
mechanism of their high efficiency.
Clinical relevance of lentiviral vector-mediated silencing
of TNF-a
Clinical reports suggest that anti-TNF-a drugs, such as
etanercept [7,28,29] and infliximab [25,30], have the potential
to relieve neuropathic pain caused by sciatica or disc herniation. In
addition, HIV chemotherapy may lead to peripheral neuropathy
caused by the massive release of TNF-a in serum and TNF-a
therapy for cancer was shown to cause peripheral neuropathy
[68,69]. Thus, silencing TNF-a, an initiator of the immune
cascade, could be a therapeutic target for different types of
neuropathic pain. However, anti-TNF-a drugs administered
systemically is associated with many side effects, e.g., general
immunosuppression in patients. The strategy used in this study
addresses this problem because the gene was selectively delivered
locally to the injury site. There are many potential clinical
applications for the treatment method developed in this study. On
the other hand, we must also contend with potential lentiviral
toxicity. Our data showed the TNF-a mRNA expression ratio
increased slightly in the LV-GFP group compared with SNT only
(no infection), which might be have been induced by the gene
delivery of lentiviral vectors, GFP, and/or undesired proteins
remaining in the preparation of lentiviral vectors after the
purification processes.
Considering the gene therapy of sensory neuronopathy, we
previously reported the intrathecal administration of DRG-
targeting fiber-modified helper-dependent adenovirus (HDAd)
vectors [70]. The fiber-modified vectors display high affinities for
neurons compared to the wild type Ad vectors. However, injection
onto spinal nerve of lentiviral vectors showed quite high
transduction efficiency to DRG neurons, which seems to be as
good as, if not better than, the fiber-modified HDAd vectors. As
some psuedtyped lentiviral vectors generally have high tropism to
neurons compared with adenoviral vectors, local injection of
lentiviral vectors showed high performance without recombination
like as the modification of fiber protein. Moreover, the target gene
delivered by lentiviral vectors can be integrated into the nuclei of
neuronal cells leading to stable and long-term expression of
therapeutic genes [71]. It obviates the necessity for repeated
injections which might lead to an immune response. Therefore, we
believe that lentiviral vectors may be the optimal vector for long-
term therapy and may be ideal for the treatment of sensory
neuronopathies or chronic neuropathic pain as this study.
In conclusion, we presented a strategy to relieve neuropathic
pain using lentiviral shRNA vectors. Our results support previous
evidence for TNF-a in the pathogenesis of neuropathic pain. In
addition, we showed that TNF-a silencing by lentiviral shRNA
vectors protects injured DRG neurons from apoptosis. Silencing
TNF-a by lentiviral vector-mediated gene transfer targeted to
DRGs with injection onto injury site of spinal nerve may provide a
novel therapeutic alternative for the treatment of neuropathic
pain.
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